Yousif M H, Thulesius O
Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University.
J Pharm Pharmacol. 1998 Jun;50(6):681-5. doi: 10.1111/j.2042-7158.1998.tb06905.x.
The objective of this study was to assess the tocolytic activity of meloxicam, a novel cyclooxygenase-2 inhibitor, in a comparative study with the non-steroidal anti-inflammatory drug, indomethacin. The in-vitro tocolytic effect of meloxicam and indomethacin (10(-9)-10(-5)M) was evaluated on spontaneously-contracting uterine strips from non-pregnant rats and from rats at various stages of pregnancy. The rhythmic motility of the strips was reproducibly maintained over several hours. The effect of drugs was evaluated from the extent of inhibition of the frequency and amplitude of contractions. Both indomethacin and meloxicam induced dose-dependent inhibitory effects, with meloxicam being slightly more potent in all groups studied, particularly in early pregnancy. These results suggest that meloxicam, which has fewer side-effects than cyclooxygenase-1 inhibitors, could be a potentially useful tocolytic agent in the treatment of premature labour.
本研究的目的是在一项与非甾体抗炎药吲哚美辛的对比研究中，评估新型环氧化酶-2抑制剂美洛昔康的安胎活性。在来自未孕大鼠和处于不同妊娠阶段大鼠的自发收缩子宫条上，评估了美洛昔康和吲哚美辛（10⁻⁹ - 10⁻⁵M）的体外安胎作用。子宫条的节律性运动在数小时内可重复维持。根据对收缩频率和幅度的抑制程度来评估药物的作用。吲哚美辛和美洛昔康均产生剂量依赖性抑制作用，在所有研究组中，美洛昔康的效力略强，尤其是在妊娠早期。这些结果表明，与环氧化酶-1抑制剂相比副作用更少的美洛昔康，可能是治疗早产的一种潜在有用的安胎药物。
